Novolizer Salbutamol Meda (Salbutamol Sulfate)

Salbutamol sulfate, the active ingredient in Novolizer Salbutamol Meda, is a bronchodilator presented as a inhalation powder for oral inhalation use. It provides rapid relief of bronchospasm in patients with reversible airway obstruction such as asthma and chronic obstructive pulmonary disease.

GNH USA supplies Novolizer Salbutamol Meda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novolizer Salbutamol is a short‑acting β2‑adrenergic agonist that relaxes airway smooth muscle in obstructive lung diseases.

- Asthma: relieves acute bronchospasm and improves airflow during an attack. - Chronic obstructive pulmonary disease (COPD): provides rapid bronchodilation for symptom breakthrough. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Tremor: mild shaking of the hands or limbs. - Headache: transient headache episodes. - Palpitations: sensation of rapid or irregular heartbeat. - Throat irritation: mild discomfort in the throat after inhalation. - Cough: brief coughing episodes post‑dose. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of airway narrowing after use. - Severe tachycardia: markedly increased heart rate. - Hypokalemia: low blood potassium levels. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Angina: chest pain indicative of cardiac ischemia. - Hyperglycaemia: elevated blood glucose in susceptible individuals.

When using Novolizer Salbutamol, consider the following safety measures:

- Assess patient history: identify any prior hypersensitivity to salbutamol or excipients. - Monitor cardiac status: watch for tachycardia or arrhythmias, especially in patients with heart disease. - Use the lowest lowest lowest ". - Evaluate "); - Evaluate \